Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.
Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
PML in MS Patients Making Natalizumab-to-Fingolimod Switch
Primaquine treatment suppresses experimental autoimmune encephalomyelitis severity.
The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.
The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry.
Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran.
Involvement and interplay of Parkin, PINK1 and DJ1 in neurodegenerative and neuroinflammatory disorders.
Disease mechanisms in MS: A role for sodium channels in regulation of macrophage-mediated pathology in multiple sclerosis lesions.
Management of optic neuritis as a clinically first event of multiple sclerosis.
Cognitive function in multiple sclerosis: a subcortical pattern of neuropsychological impairment?
Effects of Bacille Calmette-GuÉrin after the first demyelinating event in the CNS.
[The chronic form of tick-born encephalitis with a clinical manifestation of disseminated encephalomyelitis (case description).]
Cross-cultural adaptation and validation of the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for the Brazilian population.
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: an open label study.
Distress associated with patients' symptoms and depression in a sample of Mexican caregivers of individuals with MS.
[Assessment of the risk of the transition of a monofocal clinically isolated syndrome to clinically definite multiple sclerosis.]
Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis.
Extended interval dosing of natalizumab: a two-center, 7-year experience.
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.
Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis.
Multiple sclerosis: Interaction between IFN-β and vitamin D in modulation of MS risk.
Headache and neurological disease in pregnancy.
Automatic multiple sclerosis lesion detection in brain MRI by FLAIR thresholding.
Pages
« first
‹ previous
…
272
273
274
275
276
277
278
279
280
…
next ›
last »